PROCEPT BioRobotics (PRCT) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.47
- EPS estimate
- −$0.46
- EPS surprise
- −1.75%
- Revenue surprise
- +1.86%
- Revenue
- $94.5M
- Revenue estimate
- $92.8M
- Reported
- Aug 4, 2026
PROCEPT BioRobotics reported Q2 2026 results on August 4, 2026. The company lost $0.47 per share, slightly wider than the $0.46 loss expected, a 1.75% miss. Revenue of $94.5 million beat the $92.8 million estimate by about 2%. Compared with Q2 2025, revenue grew about 19% from $79.2 million, while the loss widened from $0.35 per share.
Every quarter in the table is a loss. Annual revenue rose from $75.0 million in 2022 to $136.2 million in 2023, $224.5 million in 2024 and $308.1 million in 2025. Annual losses were $1.96 per share in 2022, $2.24 in 2023, $1.76 in 2024 and $1.71 in 2025. Q2 2026 set the quarterly revenue high in the table. Year-over-year revenue growth topped 50% in every quarter from Q3 2022 to Q1 2025, and was about 19–20% in the first half of 2026. Over 20 quarters, PROCEPT beat EPS estimates 11 times and missed 9 times.
PROCEPT reported Q3 between October 28 and November 4 in each of the past five years. That points to late October or early November 2026 for the Q3 2026 report. It will show how revenue growth and the quarterly loss compare with a year earlier.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 4, 2026 | −$0.46 | −$0.47 | −1.75% | $94.5M | SEC |
| Q1 2026 | Apr 29, 2026 | −$0.56 | −$0.56 | +0.52% | $83.1M | SEC |
| Q4 2025 | Feb 25, 2026 | −$0.32 | −$0.53 | −63.58% | $76.4M | SEC |
| Q3 2025 | Nov 4, 2025 | −$0.41 | −$0.38 | +7.88% | $83.3M | SEC |
| Q2 2025 | Aug 6, 2025 | −$0.42 | −$0.35 | +15.66% | $79.2M | SEC |
| Q1 2025 | Apr 24, 2025 | −$0.49 | −$0.45 | +8.24% | $69.2M | SEC |
| Q4 2024 | Feb 25, 2025 | −$0.34 | −$0.35 | −3.21% | $68.2M | SEC |
| Q3 2024 | Oct 28, 2024 | −$0.49 | −$0.40 | +18.13% | $58.4M | SEC |
| Q2 2024 | Aug 1, 2024 | −$0.52 | −$0.50 | +4.34% | $53.4M | SEC |
| Q1 2024 | May 1, 2024 | −$0.56 | −$0.51 | +8.16% | $44.5M | SEC |
| Q4 2023 | Feb 27, 2024 | −$0.44 | −$0.54 | −23.20% | $43.6M | SEC |
| Q3 2023 | Nov 1, 2023 | −$0.53 | −$0.51 | +2.95% | $35.1M | SEC |
| Q2 2023 | Jul 27, 2023 | −$0.57 | −$0.56 | +1.86% | $33.1M | SEC |
| Q1 2023 | Apr 27, 2023 | −$0.58 | −$0.63 | −8.30% | $24.4M | SEC |
| Q4 2022 | Feb 28, 2023 | −$0.54 | −$0.63 | −15.74% | $23.8M | SEC |
| Q3 2022 | Nov 3, 2022 | −$0.48 | −$0.51 | −5.96% | $20.3M | SEC |
| Q2 2022 | Aug 5, 2022 | −$0.48 | −$0.43 | +10.79% | $16.7M | — |
| Q1 2022 | May 5, 2022 | −$0.47 | −$0.39 | +17.46% | $14.2M | SEC |
| Q4 2021 | Mar 8, 2022 | −$0.39 | −$0.42 | −7.69% | $10.1M | SEC |
| Q3 2021 | Nov 4, 2021 | −$0.41 | −$1.22 | −197.56% | $8.7M | SEC |
Quarterly revenue
Frequently asked questions
When did PROCEPT BioRobotics (PRCT) last report earnings?
PROCEPT BioRobotics last reported on Aug 4, 2026, covering fiscal Q2 2026.
Did PRCT beat earnings estimates?
No. PROCEPT BioRobotics reported EPS of −$0.47 for Q2 2026 against a −$0.46 estimate — a 1.75% miss.
How much revenue did PRCT report last quarter?
PROCEPT BioRobotics reported $94.5M in revenue for Q2 2026, against a consensus estimate of $92.8M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.